Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Merck Sharp & Dohme LLC
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Exelixis
Amgen
EMD Serono
The Methodist Hospital Research Institute
Seagen Inc.
Bayer
Sotio Biotech Inc.
Eli Lilly and Company
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Rondo Therapeutics
Bayer
Mayo Clinic
Dragonfly Therapeutics
Merck Sharp & Dohme LLC
Eli Lilly and Company
Pfizer
Emory University
Pfizer
Seagen Inc.
Incendia Therapeutics
Shanghai Henlius Biotech
Amgen
University of Rochester
Werewolf Therapeutics, Inc.
Royal Marsden NHS Foundation Trust
City of Hope Medical Center
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Novartis
Bio-Thera Solutions
AbelZeta Inc.
Amgen
Sairopa B.V.
Rutgers, The State University of New Jersey
Daiichi Sankyo
Coherus Oncology, Inc.
Merck Sharp & Dohme LLC
Nanobiotix
Hummingbird Bioscience
Peter MacCallum Cancer Centre, Australia
Tempest Therapeutics
Asher Biotherapeutics, Inc.
Valo Therapeutics Oy
Epkin
Takeda
Institute of Cancer Research, United Kingdom